Anzeige
Mehr »
Login
Sonntag, 05.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Cannabisaktien sollten nun den S&P um 60% outperformen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Übersicht Suchergebnisse zum Thema OTSUKA

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
DiOtsuka Holdings GAAP EPS of ¥142.59, revenue of ¥519.52B; reaffirms FY24 outlook3
09.04.H LUNDBECK A/S: Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD88
03.04.Otsuka, Click Therapeutics snag FDA clearance for depression therapy app199
02.04.FDA clears first DTx for depression from Otsuka, Click3
28.03.Otsuka and Lundbeck's schizophrenia treatment gains EC approval4
06.03.Dong-A Otsuka pledges 'zero plastic' on 45th anniversary3
26.02.iBio, Inc.: iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka683- Deal includes $1 million upfront and potential future milestone payments - - iBio's proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates - BRYAN...
► Artikel lesen
19.02.FDA grants breakthrough therapy status for Otsuka's IgAN drug3
16.02.Otsuka wins FDA breakthrough therapy designation for IgAN drug2
13.02.Otsuka's Alzheimer's drug AVP-786 fails phase 3 trial4
08.02.Otsuka's Abilify Maintena: dual drug expiry signals sales decline1
01.02.Otsuka Corporation GAAP EPS of ¥297.99, revenue of ¥1.47B2
19.12.23Otsuka pays $65M cash for European rights to Ionis' phase 3 rare disease med7
19.12.23Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka7
19.12.23Ionis and Otsuka sign agreement for hereditary angioedema therapy5
18.12.23Ionis Pharmaceuticals enters into a license agreement with Otsuka8
11.12.23Otsuka sees highest patent filings and grants during July in Q3 20234
01.12.23Otsuka Buys US Supplement Maker Bonafide Health for $425 Million4
14.11.23Otsuka Pharmaceutical submits NDA for voclosporin in Japan5
13.11.23FDA rules Otsuka marketing claim overstates Rexulti efficacy, threatening cornerstone of huge TV push2
Seite:  Weiter >>